• 首页
  • 身体密码
  • 养生资讯
  • 医学前沿
  • 营养识堂
  • 保健知识
  • 健康饮食

Yiling Pharmaceutical Lianhua Qingwen Capsule helps prevent and control the global epidemic

04-10   

On April 4, 2020, Phoenix TV broadcast a report on Yiling Pharmaceutical. It was reported that the global epidemic continued to worsen. At the China-Europe anti-epidemic exchange meeting, the recovery rate of patients treated with Lianhua Qingwen Capsule of Yiling Pharmaceutical co., LTD was as high as 91.5 percent, which has become a hot spot. Since 2004, Lianhua Qingwen Capsule has been listed by the national health commission of China, the state administration of traditional Chinese medicine and other departments in the treatment of influenza and other respiratory diseases for more than 20 times. It has played an important role in the prevention and control of major epidemics. On March 30, Lianhua Qingwen Capsule was approved by the ministry of health of Thailand for the registration of modern herbal medicine, which indicated that Yiling pharmaceutical co., a representative of modern Chinese medicine enterprises in China, had the qualification to sell Lianhua Qingwen Capsule as a drug in the Thai market.

Lianhua Qingwen Capsule helps prevent and control the global epidemic


At the beginning of 2020, COVID - 19 outbreak occurred in Wuhan, China, as the medicine recommended by the national health commission of China in the "diagnosis and treatment scheme of pneumonia infected by novel coronavirus", the market demand of Lianhua Qingwen capsules (granules) produced by Yiling Pharmaceutical co., LTD surged. In order to ensure market supply and help prevent and control the epidemic, all the production lines of Yiling Pharmaceutical co., ltd. are racing against time to produce Lianhua Qingwen products within 24 hours." When the outbreak came, we immediately donated 10 million yuan of Lianhua Qingwen capsules to the Red Cross society of China, of which 5 million yuan of Lianhua Qingwen capsules were transported overnight to the epidemic area in Wuhan to ensure the market demand. At the same time, we also donated products to foreign countries, such as Iraq and Italy. Yiling Pharmaceutical general manager Wu Xiangjun said in an interview.

In the covid-19 prevention and control programs successively released by more than 20 provinces and cities including Hubei, Guangzhou, Zhejiang, Shandong and Hebei, Lianyanghua Qingwen capsules (granules) are recommended. In an interview, Jia zhenhua, director of the Yiling medical research institute, pointed out that "the formula of Lianhua Qingwen is to include the pathogenesis of such diseases as exogenous febrile diseases (respiratory diseases caused by viruses in western medicine) and its treatment drugs."


The good curative effect of Lianhua Qingwen capsule is due to its characteristic of active intervention in multi-target therapy. Hou Yunlong, deputy director of the new drug evaluation center of Yiling medical research institute, told the reporter: "We found that Lianhua Qingwen has certain antiviral replication ability at the cell. When the virus infects the host cell, the host cell will have a certain immune response, and this immune response will release a number of pro-inflammatory factors.”

The overseas business layout of Yiling keeps accelerating

While actively promoting the fight against the "epidemic", Yiling Pharmaceutical's overseas business layout is also accelerating. On March 30, Yiling pharmaceutical announced that it had obtained the approval from the ministry of health of Thailand for the registration of modern herbal medicine, and approved Lianhua Qingwen capsules to comply with the registration of Thailand's modern herbal medicine standards, which brought more international recognition to traditional Chinese medicine.

"Through this outbreak, there has been a significant change in western European and American countries' understanding of traditional Chinese medicine." Zhao Shaohua, deputy general manager of Yiling Pharmaceutical co., said in an interview, "Lianhua Qingwen has been sold in some countries for many years. It used to be mainly used to treat flu, and there was a normal sale every year. Following the global outbreak of covid-19 this year, the demand for Lianhua Qingwen has increased exponentially. This has laid a very good foundation for Lianhua Qingwen 's future sales in the international market.

At present, Yiling Pharmaceutical products such as Tongxinluo capsule, Lianhua Qingwen capsule, Shensong Yangxin capsule, Qiliqiangxin capsule, Yangzheng Xiaoji capsule have been registered and sold in Korea, Vietnam, Russia, Canada, Singapore, Indonesia and other countries. Tongxinluo capsule has also been included in Vietnam's national health insurance directory. Lianhua Qingwen capsule has been registered in Hong Kong and Macao, as well as in Canada, Mozambique, Indonesia, Brazil, Romania, Thailand and other countries, and has carried out phase II clinical study in the United States.

On the internationalization of traditional Chinese medicine, Wu Xiangjun told reporters: "Yiling Pharmaceutical has set up the world federation of traditional Chinese medicine collateral disease branch, as well as in Canada, Europe, northern Europe. The theory of collateral disease has become a window for the world to understand the culture of traditional Chinese medicine, and a bright spot for the culture of traditional Chinese medicine to enter the world. With the deepening of people's understanding of traditional Chinese medicine and its wide spread, I believe traditional Chinese medicine will be a bright name card for China's internationalization in the future."



免责声明:本文转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责,亦不负任何法律责任。 本站所有资源全部收集于互联网,分享目的仅供大家学习与参考,如有版权或知识产权侵犯等,请给我们留言。

最新

  • 智能超声新未来| “凤眼S-Fetus”技术全球首发

    5月21日,由开立医疗主办的“凤眼S-Fetus新技术发布会”在医疗器械创新之都——深圳领航启幕,同时于银川、武汉、成都、合肥、南京、郑州、长沙等十多个会场同步连线,广邀全国各地众多专家同仁相聚云端,共襄盛会。十余名国内与国际妇产和超声专家学者莅临发布会,与全球超声同道共同见证这一突破性的技术亮相——第四代人工智能产前超声筛查技术“凤眼S-Fetus”。
  • 和润科技智能核酸采样整体解决方案|助力打造“15分钟核酸服务圈”

    按照国家卫健委加强新冠肺炎核酸检测能力建设的要求,为快速提升新冠肺炎核酸检测能力,满足大规模新冠肺炎核酸检测需求。实现建立步行15分钟核酸“采样圈”,便于公众就近就便接受核酸检测的服务,这对城市的常态化布局带来了新的要求。
  • 专注研发实力领跑,和润科技获专精特新“小巨人”称号

    今年2月,北京市经信局正式公示了2021年第二批专精特新“小巨人”企业评选结果,和润科技凭借其在公共安全领域的卓越表现和行业影响力,获此殊荣。本次获选距离和润科技取得北京市“专精特新”企业认定称号仅有5个月之隔。晋升“小巨人”,不仅是对该公司经营理念、研发实力,以及其在整个产业链中所发挥的重要作用的再次认可,更为公司实现快速成长,打造行业龙头企业,缔造了契机。
  • 振东制药助力疫情防控,二次创新发挥中医药抗疫优势

    尽管新冠疫苗已在多国大规模接种,但全球疫情依然持续,变异病毒给疫苗带来的挑战也让世界各国意识到开发治疗药物的急迫性。今年三月,世界卫生组织召开专家会议,对中医药救治新冠肺炎进行评估并在随后发布了专家评估报告,充分肯定了中医药抗击新冠肺炎疫情的贡献。在疫情防控中始终坚持中西医结合、中西药并用,以振东制药为代表的中医药企业正充分发挥中医药在抗击新冠肺炎疫情中的独特优势。
  • 首部生物经济五年规划强调中药质量 振东制药填补行业标准空白

    近日,为贯彻落实党中央、国务院决策部署,系统谋划和整体推动我国生物经济高质量发展,经国务院同意,国家发展改革委印发了《“十四五”生物经济发展规划》,《规划》明确了大力夯实生物经济创新基础、培育壮大生物经济支柱产业、积极推进生物资源保护利用、加快建设生物安全保障体系、努力优化生物领域政策环境等5个方面的具体任务。在培育壮大生物经济支柱产业方面,规划提出选育一批中药材良种,从源头加强中药质量保障,推动传统中药材种植产业转型升级,建立中药材生态种植体系。开发一批优质中药,支持中医药标准化工作,建设中医药标准物质库、质控标准体系、信息数据平台。
  • 视力保健整合行业招商运营资源的专业平台

    现在这个时代更多的人要应付快节奏的学习、工作和生活,面对越来越多的竞争和挑战,人们的生理和心理都不断衰弱、老化和病变,目前近视,刺神、散光、视病荣,眼干,眼涩,眼涨,迎风流泪等各种青少年视力疾病与慢性“职业病”发生率连年上升,且越来越呈现年轻化趋势。有数据显示,中国近视患者多达6亿,占中国总人口的近50%。在未来的几十年,健康产业,眼部健康行业将是未来人们注重发展的一大趋势。
  • 花瑾堂 | 千金小姐双向发酵口服液好在哪?

    女性健康是当下备受关注的一个话题,女性至美的力量觉醒,大多人开始认识到爱自己的重要性。不管是追求形体健康美、自然外在美,还是生理和心理的双重美,都是女性意识的觉醒。
  • 全国首家,双核驱动!海鸥数字医疗器械产业园今日开园

    2022年2号文件《关于支持贵州在新时代西部大开发上闯新路的意见》为贵州省数字产业发展按下了“快进键”。在这一背景下,贵州省政府基于国家大数据中心的独特区位优势,开始大力推动互联网医疗和数字医疗融合发展,致力于打造全国首个互联网医疗和数字医疗器械双核驱动的省级示范产业园。
  • 疫情后生物医药产业发展契机和技术创新 | 乐土沃森院士论坛1亮点回顾

    2022年5月8日,由深圳市大鹏新区组织人事局作为指导单位,乐土生命科技与深圳市生命科学与生物技术协会联合主办的“乐土沃森大讲堂院士论坛第一期”在乐土沃森生命科技中心举行。
  • 威远保健养生整合行业招商运营资源的专业平台

    中医流传一句话:“春养肝,夏养心,秋养肺,冬养肾,四季养脾胃。”中医学认为:“人与天地相应”,意思是人体的生理机理应与四季气候的变化密切相应。那么养生汤!就是具有食疗、养生效果。是根据传统中医原理,使用食材搭配、药食同源等方法,用某种、几种食材加工制作出来的一种有营养的汤。从功效上说,养生汤适合调养体质,养生保健。它是我们中华民族的一份宝贵文化的遗产。

友情链接

Back to top
      联系我们   SiteMap